ABL Diagnostics Logo

ABL Diagnostics

ISIN: FR001400AHX6 | Ticker: ABLD | LEI: 9695002UO0UHM0VKRH38

About ABL Diagnostics

Company Description

Advanced Biological Laboratories (ABL), S.A., is a diagnostic and medical software company founded in 2000 as a spin-off from CRP-Santé (https://www.lih.lu/) Luxembourg.

ABL’s products offer to infectious disease clinicians, virology and microbiology laboratories.

Assays and standalone software systems for accredited laboratories (i.e. ISO 15189), mainly for microbiology applications (related to HIV, SARS-CoV-2, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, 16s RNA…) for clinical genotyping through sequencing (DeepChek®), DNA and RNA detection and quantification (UltraGene®), including powerful downstream analysis software applications fully integrated with knowledge databases and analysis systems for capillary and high-throughput Next Generation Sequencing data.

Clinical software applications for infectious diseases units

IT dashboards and clinical database aggregation applications for research and clinical management

Year founded


Served area



Bât E1 42 Rue Olivier Métra, 75020 Paris – France

Filings & Publications

Shareholder information

Shares outstanding



Jan. 1, 2020

Stock exchange(s)

Euronext Paris



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.